Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2

Human tumor heterogeneity promotes therapeutic failure by increasing the likelihood of resistant cell subpopulations. The PARP-1 inhibitor olaparib is approved for use in BRCA-mutated ovarian cancers but BRCA2-reversion mutations lead to functional homologous recombination repair (HRR) and olaparib...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Rytelewski, Mateusz, Vareki, Saman Maleki, Mangala, Lingegowda S., Romanow, Larissa, Jiang, Dahai, Pradeep, Sunila, Rodriguez-Aguayo, Christian, Lopez-Berestein, Gabriel, Figueredo, Rene, Ferguson, Peter J., Vincent, Mark, Sood, Anil K., Koropatnick, James D.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991495/
https://ncbi.nlm.nih.gov/pubmed/26959114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7883
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares